ARCH Venture Partners X, LLC

Insider Reports History

Location
8755 W. Higgins Road, Suite 1025, Chicago, IL
Signature
ARCH Venture Fund X, L.P. By: ARCH Venture Partners X, L.P., its General Partner By: ARCH Venture Partners X, LLC, its General Partner By: /s/ Mark McDonnell, as Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by ARCH Venture Partners X, LLC:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Neumora Therapeutics, Inc. 10%+ Owner Common Stock 12.2M $22.2M $1.82 Oct 27, 2025 By ARCH Venture Fund X, L.P.
Neumora Therapeutics, Inc. 10%+ Owner Common Stock 11.9M $21.6M $1.82 Oct 27, 2025 By ARCH Venture Fund X Overage, L.P.
Neumora Therapeutics, Inc. 10%+ Owner Common Stock 6.05M $15.8M $2.61 Oct 27, 2025 By ARCH Venture Fund XII, L.P.
Verve Therapeutics, Inc. 10%+ Owner Common Stock, par value $0.001 1.25M $12.5M $10.00 Jun 21, 2021 ARCH Venture Fund X Overage, L.P.
Verve Therapeutics, Inc. 10%+ Owner Common Stock, par value $0.001 1.25M $12.5M $10.00 Jun 21, 2021 ARCH Venture Fund X, L.P.
Erasca, Inc. 10%+ Owner Common Stock 5.53M $8.79M $1.59 Jul 20, 2021 By ARCH Venture Fund X, L.P.
Erasca, Inc. 10%+ Owner Common Stock 5.53M $8.79M $1.59 Jul 20, 2021 By ARCH Venture Fund X Overage, L.P.
Prime Medicine, Inc. 10%+ Owner Common Stock 6.23M $7.91M $1.27 Aug 1, 2025 By ARCH Venture Fund XII, L.P.
Prime Medicine, Inc. 10%+ Owner Common Stock 6.13M $7.78M $1.27 Aug 1, 2025 By ARCH Venture Fund X, L.P.
Prime Medicine, Inc. 10%+ Owner Common Stock 6.13M $7.78M $1.27 Aug 1, 2025 By ARCH Venture Fund X Overage, L.P.
Neumora Therapeutics, Inc. 10%+ Owner Common Stock 2.32M $4.23M $1.82 Oct 27, 2025 By ARCH Venture Fund VIII Overage, L.P.
Neumora Therapeutics, Inc. 10%+ Owner Common Stock 1.39M $2.52M $1.82 Oct 27, 2025 By ARCH Venture Fund VII, L.P.
Erasca, Inc. 10%+ Owner Series A Preferred Stock 0 Jul 20, 2021 By ARCH Venture Fund X, L.P.
Erasca, Inc. 10%+ Owner Series A Preferred Stock 0 Jul 20, 2021 By ARCH Venture Fund X Overage, L.P.
Erasca, Inc. 10%+ Owner Series B-1 Preferred Stock 0 Jul 20, 2021 By ARCH Venture Fund X, L.P.
Erasca, Inc. 10%+ Owner Series B-1 Preferred Stock 0 Jul 20, 2021 By ARCH Venture Fund X Overage, L.P.
Erasca, Inc. 10%+ Owner Series B-2 Preferred Stock 0 Jul 20, 2021 By ARCH Venture Fund X, L.P.
Erasca, Inc. 10%+ Owner Series B-2 Preferred Stock 0 Jul 20, 2021 By ARCH Venture Fund X Overage, L.P.
Verve Therapeutics, Inc. 10%+ Owner Series A-2 Convertible Preferred Stock 0 Jun 21, 2021 Indirect
Verve Therapeutics, Inc. 10%+ Owner Series A Convertible Preferred Stock 0 Jun 21, 2021 Indirect

Insider Reports Filed by ARCH Venture Partners X, LLC

Symbol Company Period Transactions Value $ Form Type Date Filed Role
NMRA Neumora Therapeutics, Inc. Oct 27, 2025 1 $5M 4 Oct 29, 2025 10%+ Owner
PRME Prime Medicine, Inc. Aug 1, 2025 1 $10M 4 Aug 1, 2025 10%+ Owner
MAZE Maze Therapeutics, Inc. Jan 30, 2025 0 $0 3 Jan 30, 2025 10%+ Owner
PRME Prime Medicine, Inc. Feb 15, 2024 1 $20M 4 Feb 20, 2024 10%+ Owner
NMRA Neumora Therapeutics, Inc. Dec 8, 2023 2 $0 4 Dec 12, 2023 10%+ Owner
NMRA Neumora Therapeutics, Inc. Sep 19, 2023 11 $25.5M 4 Sep 20, 2023 10%+ Owner
NMRA Neumora Therapeutics, Inc. Sep 19, 2023 11 $25.5M 4 Sep 20, 2023 10%+ Owner
NMRA Neumora Therapeutics, Inc. Sep 14, 2023 0 $0 3 Sep 14, 2023 10%+ Owner
NMRA Neumora Therapeutics, Inc. Sep 14, 2023 0 $0 3 Sep 14, 2023 10%+ Owner
PRME Prime Medicine, Inc. Oct 24, 2022 8 $13.6M 4 Oct 26, 2022 10%+ Owner
PRME Prime Medicine, Inc. Oct 19, 2022 0 $0 3 Oct 19, 2022 10%+ Owner
ERAS Erasca, Inc. Jul 20, 2021 8 $0 4 Jul 20, 2021 10%+ Owner
ERAS Erasca, Inc. Jul 15, 2021 0 $0 3 Jul 15, 2021 10%+ Owner
VERV Verve Therapeutics, Inc. Jun 21, 2021 6 $0 4 Jun 23, 2021 10%+ Owner